Who we are What we do Who is using our data Steering committee Operating team Trialists Former contributors Publications Data sharing Update: every 2 weeks
Mapping Treatments tested
Pharmacologic treatments Nonpharmacologic treatments
Living mapping Living evidence synthesis (Vaccine RCTs) Living evidence synthesis (Vaccine RCTs - Variants) Living evidence synthesis (Observational studies - Variants)
Preventive treatments
☰

COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment		 Full description
Intervention 1 Intervention 2
ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, Lancet, 2021 ()
Com-COV

Full text
Commentary
 RNA based vaccine

1 dose ChAdOx1/ 1 dose BNT162b2

1 dose BNT162b2 /1 dose ChAdOx1

2 doses ChAdOx1

2 doses BNT162b2

 RCT
Phase 2 		Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description